Gilead Sciences

Research only

GILD · Tracked drugs and regulatory events

Tracked programs

1 program

HIV pre-exposure prophylaxis

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releaseinvestors.gilead.com

Sponsor reports acceptance for a once-weekly oral PrEP formulation, with a February 2, 2027 FDA target.

Sponsor presentation links lenacapavir to published small-molecule capsid-inhibitor research; it does not establish once-weekly approval.